Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 217,471,790 papers from all fields of science
Search
Sign In
Create Free Account
BMS-650032
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
asunaprevir
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor.
Kathy Mosure
,
J. Knipe
,
+9 authors
M. Sinz
Journal of Pharmacy and Science
2015
Corpus ID: 29403845
Asunaprevir (ASV; BMS-650032), a low nanomolar inhibitor of the hepatitis C virus (HCV) NS3 protease, is currently under…
Expand
2015
2015
Characterization of ADME properties of [14C]asunaprevir (BMS-650032) in humans
J. Gong
,
T. Eley
,
+7 authors
Wenying Li
Xenobiotica; the fate of foreign compounds in…
2015
Corpus ID: 23398078
Abstract 1. Asunaprevir (ASV, BMS-650032), a highly selective and potent NS3 protease inhibitor, is currently under development…
Expand
Review
2015
Review
2015
Asunaprevir (BMS-650032) for the treatment of hepatitis C virus
N. Akamatsu
,
Y. Sugawara
,
N. Kokudo
Expert Review of Anti-Infective Therapy
2015
Corpus ID: 7031076
Asunaprevir, a second-generation NS3 protease inhibitor of hepatitis C virus (HCV), exhibits strong antiviral activity against…
Expand
Highly Cited
2014
Highly Cited
2014
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection.
P. Scola
,
Li-Qiang Sun
,
+47 authors
F. Mcphee
Journal of Medicinal Chemistry
2014
Corpus ID: 34947978
The discovery of asunaprevir (BMS-650032, 24) is described. This tripeptidic acylsulfonamide inhibitor of the NS3/4A enzyme is…
Expand
Highly Cited
2012
Highly Cited
2012
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
F. Mcphee
,
A. Sheaffer
,
+16 authors
P. Scola
Antimicrobial Agents and Chemotherapy
2012
Corpus ID: 26442738
ABSTRACT Asunaprevir (ASV; BMS-650032) is a hepatitis C virus (HCV) NS3 protease inhibitor that has demonstrated efficacy in…
Expand
Highly Cited
2012
Highly Cited
2012
14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO…
F. Suzuki
,
K. Ikeda
,
+11 authors
H. Kumada
2012
Corpus ID: 71134371
2012
2012
Combination Treatment with Hepatitis C Virus Protease and NS5A Inhibitors Is Effective against Recombinant Genotype 1a, 2a, and 3a Viruses
J. Gottwein
,
S. B. Jensen
,
+5 authors
J. Bukh
Antimicrobial Agents and Chemotherapy
2012
Corpus ID: 206710506
ABSTRACT With the development of directly acting antivirals, hepatitis C virus (HCV) therapy entered a new era. However, rapid…
Expand
Highly Cited
2011
Highly Cited
2011
1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS
A. Lok
,
D. Gardiner
,
+14 authors
C. Pasquinelli
2011
Corpus ID: 73136677
2011
2011
63 CHARACTERIZATION OF VIROLOGIC ESCAPE IN HCV GENOTYPE 1 NULL RESPONDERS RECEIVING A COMBINATION OF THE NS3 PROTEASE INHIBITOR BMS-650032 AND NS5A INHIBITOR BMS-790052
F. Mcphee
,
D. Hernandez
,
+6 authors
M. Gao
2011
Corpus ID: 71295657
2010
2010
761 IDENTIFICATION AND PRECLINICAL PROFILE OF THE NOVEL HCV NS3 PROTEASE INHIBITOR BMS-650032
F. Mcphee
2010
Corpus ID: 72605708
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required